Vitamin D is the most-debated supplement in longevity science. Some researchers, like Dr. JoAnn Manson (lead investigator of the landmark VITAL trial), argue the benefits are modest and limited to specific outcomes. Others point to decades of observational data showing that people with higher vitamin D levels consistently live longer. The truth sits somewhere in between — and understanding exactly where helps you decide whether to supplement.
Evidence Tier: 🥈 Silver — Strong observational evidence for mortality reduction. RCT data is mixed: most large trials show no overall mortality benefit, but a 16% reduction in cancer death emerges consistently in meta-analyses.
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Vitamin D at high doses can cause toxicity. Consult your doctor before supplementing, especially if you have kidney disease, sarcoidosis, or take certain medications.
✅ Pros
Cancer mortality reduction: Meta-analysis of 52 RCTs (75,454 participants) found a 16% lower risk of cancer death with vitamin D supplementation.
Bone and muscle health: Reduces fracture and fall risk in older adults, especially those with baseline deficiency. Large effect when combined with calcium.
Immune function: Vitamin D receptor is expressed on immune cells. Deficiency linked to higher infection rates and autoimmune disease risk.
Very safe at standard doses: No serious adverse events at 2,000-4,000 IU/day in long-term RCTs. Hypercalcemia risk is extremely low below 10,000 IU/day.
❌ Cons
No all-cause mortality benefit in RCTs: The largest trials (VITAL: 25,871 people; D-Health: 21,315 people) found no reduction in overall death rates.
No cardiovascular protection: Multiple large RCTs and meta-analyses show no effect on heart attacks, strokes, or CVD death.
Genetic variability: Your GC gene affects how well you respond to supplementation. Some people get a much bigger 25(OH)D boost from the same dose.
Toxicity possible at high doses: Hypercalcemia, kidney stones, and vascular calcification can occur with prolonged intake above 10,000 IU/day or single megadoses.
What Is Vitamin D?
Vitamin D is not actually a vitamin — it is a steroid hormone that your body produces when sunlight hits your skin. Specifically, UVB radiation converts 7-dehydrocholesterol in the skin into vitamin D3 (cholecalciferol). Your liver then converts it to 25-hydroxyvitamin D [25(OH)D], the storage form measured in blood tests. Your kidneys (and many other tissues) then convert 25(OH)D into the active hormone 1,25-dihydroxyvitamin D (calcitriol), which binds to the vitamin D receptor (VDR) found in nearly every cell in your body.
The VDR regulates over 200 genes — far beyond just calcium and bone metabolism. It influences immune function, cell growth, inflammation, and even how your cells age. This is why vitamin D status matters far beyond just bone health.
There are two main forms:
- Vitamin D3 (cholecalciferol): The form your skin makes from sunlight. Also found in animal foods like fatty fish and egg yolks. This is what most supplements contain and what the evidence supports.
- Vitamin D2 (ergocalciferol): Made by plants and fungi. Less effective at raising blood levels. Some meta-analyses suggest D3 reduces mortality while D2 does not — though this is a subgroup finding, not a definitive comparison.
How It Works
Vitamin D works through the vitamin D receptor (VDR), a nuclear receptor present in most tissues. When calcitriol binds to VDR, it pairs with the retinoid X receptor (RXR) and binds to vitamin D response elements on DNA, turning genes on or off. This affects:
- Calcium absorption: Without vitamin D, you absorb only 10-15% of dietary calcium. With adequate D, absorption jumps to 30-40%. This is why vitamin D and calcium are inseparable in bone health.
- Immune modulation: VDR is expressed on T cells, B cells, and antigen-presenting cells. Vitamin D shifts the immune system away from autoimmunity and excessive inflammation while preserving pathogen-fighting ability.
- Cell cycle control: Calcitriol promotes differentiation and apoptosis (programmed cell death) in abnormal cells — one proposed mechanism for its anti-cancer effects.
- Muscle function: VDR is present in skeletal muscle. Deficiency causes muscle weakness, which directly increases fall risk in older adults.
- Inflammation reduction: Vitamin D suppresses NF-κB signaling and reduces pro-inflammatory cytokines like TNF-α and IL-6 — key drivers of aging-related inflammation (“inflammaging”).
Why aging makes vitamin D more relevant: As you age, your skin produces less vitamin D from the same amount of sunlight. A 70-year-old produces about 25% as much vitamin D as a 20-year-old from identical sun exposure. Meanwhile, the kidneys become less efficient at converting 25(OH)D to the active hormone. The result: older adults are at much higher risk of deficiency, and the consequences — falls, fractures, immune decline — compound with age.
The Longevity Connection
🥇 Cancer Mortality
This is where the evidence is strongest. The 2019 BMJ meta-analysis of 52 RCTs found vitamin D supplementation reduced cancer death risk by 16% (RR 0.84, 95% CI 0.74-0.95). The VITAL trial itself showed a borderline 17% reduction in cancer death (HR 0.83, 0.67-1.02) that became statistically significant in a secondary analysis excluding the first 2 years of follow-up. A 2024 UK Biobank study of 335,206 participants followed for 13.77 years found that low 25(OH)D combined with insulin resistance created the highest cardiovascular risk phenotype.
🥈 All-Cause Mortality — Observational vs. RCT Divide
Here is where the evidence splits. Observational studies consistently show that people with higher 25(OH)D levels live longer. The association is strong, dose-dependent, and persists after adjustment for confounders. But the large RCTs — VITAL (25,871 participants), D-Health (21,315 participants), and others — do NOT show a reduction in all-cause mortality. The 2019 BMJ meta-analysis found RR 0.98 (0.95-1.02) for all-cause death — essentially no effect.
The key insight: most RCTs enrolled people with normal vitamin D levels at baseline (VITAL: mean 31 ng/mL). Supplementing people who are not deficient may not move the needle. In subgroup analyses of RCTs, the mortality benefit tends to concentrate in people with baseline 25(OH)D below 20 ng/mL. This is the “treating sufficiency” problem.
🥈 Bone Health and Falls
Vitamin D increases calcium absorption and muscle strength. In older adults with deficiency, supplementation reduces fall risk by ~20% and fracture risk by a similar margin — especially when combined with calcium. A 2024 RCT in postmenopausal women found that liposomal vitamin D3 (800 IU/day + calcium) increased femoral neck BMD by 2.8% vs. placebo over 24 months, with only 1 fracture in 153 treated patients vs. 8 in 153 placebo patients.
However, the 2014 BMJ umbrella review concluded that evidence does not support vitamin D alone increasing bone mineral density or reducing fracture risk — the benefit appears to require the combination with calcium, and only in those with baseline deficiency.
🥉 Immune Function
Vitamin D modulates both innate and adaptive immunity. Observational data links low vitamin D to higher rates of respiratory infections and autoimmune diseases. During the COVID-19 pandemic, multiple meta-analyses found that vitamin D supplementation reduced ICU admission rates. However, these findings are from relatively small trials, and the effect on mortality was inconsistent.
🥉 Brain Health
A 2026 prospective cohort study of 802 older adults with atrial fibrillation-associated stroke found that each 10 ng/mL lower 25(OH)D was associated with worse functional recovery (common OR 1.17), more depressive symptoms (OR 1.54 for levels below 20 ng/mL), and higher fall recurrence (IRR 1.33). VDR is expressed throughout the brain, and vitamin D regulates neurotrophic factors — but RCT data on cognitive outcomes is still sparse.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| VITAL (Manson, 2019) PMID: 30415629 |
RCT, N=25,871 2,000 IU/day D3 Median 5.3 years |
No reduction in cancer or CVD incidence. Cancer death: HR 0.83 (0.67-1.02). All-cause mortality: HR 0.99. Mean baseline 25(OH)D was 31 ng/mL — participants were not deficient. |
| Zhang Meta-Analysis (2019) PMID: 31405892 |
Meta-analysis 52 RCTs, N=75,454 |
16% reduction in cancer death (RR 0.84, 0.74-0.95). No reduction in all-cause or cardiovascular mortality. D3 trended better than D2 (P for interaction=0.04). |
| Theodoratou Umbrella Review (2014) PMID: 24690624 |
Umbrella review 107 systematic reviews 74 meta-analyses |
No “highly convincing” evidence for any outcome. Probable benefit for birth weight and dental caries in children. Evidence for fractures and BMD was weaker than commonly believed. |
| UK Biobank CVD Analysis (Luan, 2026) PMID: 42540537 |
Prospective cohort N=335,206 Median 13.77 years |
Low 25(OH)D + insulin resistance = highest MACE risk (HR 1.26). Significant additive interaction: the combination was worse than either factor alone. 4,369 attributable MACE cases. |
| Genetic Determinants Study (Alonso, 2026) PMID: 42528639 |
RCT, N=323 12K-48K IU/month 12 months |
GC gene variants strongly affect 25(OH)D response to supplementation. Some genotypes achieved target levels at lower doses; others needed higher doses. Genetic testing could personalize dosing. |
| Liposomal Vitamin D RCT (Rasool, 2026) PMID: 42567908 |
RCT, N=612 Postmenopausal women 24 months |
Liposomal D3 (800 IU/day) achieved higher 25(OH)D levels (38.2 vs. 28.5 ng/mL) and greater BMD gains than standard D3 (1,200 IU/day). Formulation technology matters. |
Dosing and Safety
Recommended Dosing
| Goal | Daily Dose | Target Blood Level | Notes |
|---|---|---|---|
| Prevent deficiency | 600-800 IU | >20 ng/mL | RDA. Bare minimum. Likely insufficient for most adults. |
| Optimal health (recommended) | 1,000-2,000 IU | 30-50 ng/mL | Range used in VITAL. Safe long-term. Test levels after 3 months. |
| Correct deficiency | 2,000-4,000 IU | >30 ng/mL | Start higher, then drop to maintenance. Check levels at 3 months. |
| Loading dose (severe deficiency) | ~5,000 IU/day or 50,000 IU/week for 8 weeks | >30 ng/mL | Under medical supervision only. Monitor calcium. |
Form Selection
- Vitamin D3 (cholecalciferol): Preferred. Better at raising and maintaining 25(OH)D levels than D2.
- With fat: Vitamin D is fat-soluble. Take with a meal containing some fat for better absorption.
- Timing: Morning with breakfast is practical. Some evidence suggests evening dosing may interfere with melatonin, but data is limited.
- Drops vs. capsules: Oil-based drops may have slightly better absorption but capsules are more convenient. Both work.
- Combined with K2: Theoretically beneficial — vitamin K2 directs calcium into bones rather than arteries. But the evidence for this combination is mostly mechanistic. No large RCT has tested D3+K2 against D3 alone for hard outcomes.
Side Effects and Safety
| Concern | Frequency | What to Know |
|---|---|---|
| Hypercalcemia (high blood calcium) | Very rare below 10,000 IU/day | Symptoms: nausea, vomiting, weakness, confusion. Requires very high doses over months. The VITAL trial (2,000 IU/day, 5.3 years) found NO excess hypercalcemia events. |
| Kidney stones | Uncommon | Risk increases when D is combined with high-dose calcium supplements (>1,000 mg/day). Adequate hydration reduces risk. If you have a history of kidney stones, discuss supplementation with your doctor. |
| Vascular calcification | Rare, high-dose only | Chronic megadoses can theoretically promote calcium deposition in arteries. The evidence is from animal studies and extreme human cases — not relevant at standard doses. |
| GI upset | Uncommon | Taking with food usually resolves this. |
Who should avoid supplementation without medical supervision:
- People with sarcoidosis or other granulomatous diseases (can overproduce calcitriol)
- People with primary hyperparathyroidism
- People with kidney disease (impaired conversion to active hormone)
- People taking thiazide diuretics (can increase calcium retention)
- People with a history of calcium-containing kidney stones
🥦 Food Sources & Equivalents
The honest answer up front: ⚠️ Food provides some vitamin D, but sunlight is your body’s real source — and food alone rarely gets you to target levels.
Can you get it from food?
Vitamin D is in only a handful of foods, mostly fatty fish, egg yolks, UV-treated mushrooms, and fortified milk. But the amounts are small compared to what your skin makes from direct sun.
| Food | Rough amount per serving (IU) |
|---|---|
| Wild salmon (3 oz) | ~600–1,000 IU |
| Farmed salmon (3 oz) | ~250 IU |
| Sardines / mackerel (3 oz) | ~200–500 IU |
| UV-exposed mushrooms (1 cup) | ~400+ IU |
| Egg yolk (1 large) | ~40 IU |
| Fortified milk (1 cup) | ~100 IU |
How much food equals the research dose?
To reach a common 2,000 IU target, you’d need roughly 4–5 servings of wild salmon a day — expensive and unrealistic. (Cod liver oil is rich but dangerous in those amounts because of vitamin A.) By contrast, 15–30 minutes of midday sun can trigger your skin to make 10,000–20,000 IU.
The bottom line
⚠️ Sun is the real source, not food. Food helps but can’t get most people to optimal levels, especially in winter or at higher latitudes. Most people — especially those targeting the 60–80 ng/mL blood levels discussed on this page — will need a supplement.
❓ Common Questions About Vitamin D
What is vitamin D and how does it work?
Vitamin D is a steroid hormone, not a true vitamin. Your skin makes it from sunlight, then your liver and kidneys activate it. It works by binding to the vitamin D receptor (VDR), which is found in nearly every cell in your body, turning hundreds of genes on and off. This affects calcium absorption, immune function, cell growth, and inflammation.
What does the evidence actually show?
The strongest evidence (Silver Tier) is for reducing cancer death — a 16% drop across 52 clinical trials. Bone health and fall prevention benefits are real but mainly in people with deficiency. Large trials show no benefit for heart disease or overall death rates when you supplement people who already have normal vitamin D levels. The key takeaway: vitamin D matters most when you are actually deficient.
What is the right dose?
For most adults, 1,000-2,000 IU of vitamin D3 per day with a fat-containing meal targets blood levels of 30-50 ng/mL. This is the range used in the largest clinical trials and is safe for long-term use. If you are deficient (below 20 ng/mL), start at 2,000-4,000 IU daily and test your levels after 3 months. Avoid single megadoses of 50,000 IU or more without a doctor’s supervision.
What are the risks and side effects?
At standard doses (up to 4,000 IU/day), vitamin D is extremely safe. The VITAL trial — 25,871 people taking 2,000 IU/day for over 5 years — found no increase in any adverse events. The main risks come from very high doses: hypercalcemia (too much calcium in your blood), kidney stones (especially when combined with calcium supplements), and — in extreme chronic overdosing — calcium buildup in arteries. These are not concerns at standard supplementation levels.
Who should avoid it?
People with sarcoidosis, primary hyperparathyroidism, advanced kidney disease, or a history of calcium kidney stones should take vitamin D only under medical supervision. If you take thiazide diuretics (a common blood pressure medication), vitamin D can increase calcium levels and needs monitoring. Everyone else can safely supplement at standard doses, but testing your blood level first lets you know whether you need it in the first place.
The Bottom Line
Evidence hierarchy (strongest to weakest):
- Cancer mortality reduction: 16% lower death from cancer. Consistently found in meta-analyses. The single most compelling reason to maintain adequate vitamin D.
- Bone and fall protection: Works, but mainly in people with deficiency. Effect is amplified when combined with calcium.
- Immune support: Plausible mechanism, some trial support, but effect size is modest in most studies.
- All-cause mortality: Strong observational signal, but RCTs don’t confirm a benefit — likely because trials enrolled people who were already sufficient.
- Cardiovascular protection: Not supported by large RCTs. Observational associations are likely confounded.
Our verdict: Vitamin D is a “test, don’t guess” supplement. Get your 25(OH)D level checked before you start supplementing. If you are below 20 ng/mL, supplementation is strongly indicated — the evidence for benefit in deficient populations is robust. If your level is 20-30 ng/mL, modest supplementation (1,000-2,000 IU/day) is reasonable. If you are above 30 ng/mL, the evidence suggests little additional benefit from further supplementation — you are already in the range where large trials showed no effect.
Who it is for: Almost everyone with low sun exposure, darker skin (which produces less vitamin D from sunlight), older adults (whose skin produces less D), and anyone with a measured deficiency. The combination of aging skin, reduced outdoor time, and widespread sunscreen use means the majority of adults over 50 could benefit.
Who can skip it: People who get regular, meaningful sun exposure (15-30 minutes of midday sun on arms and legs, most days), those with blood levels consistently above 30 ng/mL, and those who eat significant amounts of fatty fish daily.
Medical Disclaimer: This page is for informational purposes only and does not constitute medical advice. Vitamin D supplementation can interact with medications and certain medical conditions. Always consult your doctor before starting any new supplement, especially at doses above the RDA. Do not self-treat suspected vitamin D deficiency — get a blood test first.
Sources
- Manson JE et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019. PMID: 30415629
- Zhang Y et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019. PMID: 31405892
- Theodoratou E et al. Vitamin D and multiple health outcomes: umbrella review. BMJ. 2014. PMID: 24690624
- Luan S et al. Insulin resistance, vitamin D status, and cardiovascular risk. Front Nutr. 2026. PMID: 42540537
- Alonso N et al. Genetic determinants of response to vitamin D supplementation. Front Nutr. 2026. PMID: 42528639
- Rasool N et al. Vitamin D supplementation and bone health in post-menopausal women: a 24-month RCT. Eur J Clin Nutr. 2026. PMID: 42567908
- Li L et al. Low Vitamin D Status and Post-Stroke Depression, Falls, and Functional Recovery. Clin Interv Aging. 2026. PMID: 42542873
- Meyer MB, Pike JW. The Vitamin D Receptor Story. J Endocrinol. 2026. PMID: 42560743